Innovative immunological and target therapies for NMIBC: Recent clinical trial data shaping the future : Episode 5
Opinion
Video
BOND-003: Clinical Implications for HR BCG-Unresponsive NMIBC Treatment
Author(s):
Gary D. Steinberg, MD explains the implications of the BOND-003 results for clinical practice in treating non-muscle-invasive bladder cancer (NMIBC), highlighting the potential benefits of novel immunotherapeutic options like cretostimogene grenadenorepvec as a bladder-sparing therapy for BCG-unresponsive high-risk NMIBC, and discusses how this treatment could fit into the NMIBC treatment landscape if approved.
Video content above is prompted by the following questions:
- What could the results from BOND-003 mean for clinical practice in the treatment of patients with non-muscle-invasive bladder cancer (NMIBC)?
- What type of patient could benefit from novel immunotherapeutic options (bladder sparing therapy) for BCG-unresponsive high-risk non-muscle-invasive bladder cancer?
- If approved, how does cretostimogene fit into the treatment landscape for patients with NMBIC?
Related Videos
Related Content
